This study investigated the long-term outcomes following pegylated/standard IFN-α plus ribavirin therapy for patients with HCV-related decompensated cirrhosis. Methods: From January 2008 to January 2011, fifty consecutive, IFN-naive HCV-related decompensated cirrhosis patients treated with PEG-IFNα-2b

at 1.0-1.5 ug/kg/week or standard IFN α-2b, 3MU, thrice weekly, plus ribavirin at 800-1000 mg/day with a low accelerating dosage regimen for 48 weeks, were included in this prospective study. Results: Twenty one (42.0%) patients achieved sustained virological response (SVR), 15 (30.0%) patients were relapse, and 14 (28.0%) were non-virological response (NVR). Median follow-up off-therapy was 29 (range 8–45) months, nineteen percent (4/21) patients with SVRs, thirty-three percent (5/15) patients with relapse and 13 of 14 without virological response (92.9%) Ibrutinib concentration experienced further events of decompensation (P < 0.0001). Seven patients (14%) developed HCC Lumacaftor purchase during the observation period, including 2/21 with SVRs (9.5%), 1/15 with relapse (6.7%)

and 4 of 14 (28.6%) without virological response respectively. Complete viral suppression during treatment (SVR or relapse) were associated with a lower risk of the development of HCC when compared with NVR (over all: P = 0.048, SVR vs. Relapse: P= 0.887 , SVR vs. NVR: P = 0.045 , and Relapse vs. NVR: P = 0.089 by log-rank test). Conclusion: In decompensated cirrhotics, SVR and complete viral suppression during treatment with relapse were associated with a reducing disease progression and a lower risk of the development of HCC. Key Word(s): 1. Hepatitis C virus; 2. Cirrhosis ; 3. Antiviral therapy; 4. HCC; selleck Presenting Author: SHAOYOU QIN Additional Authors: CHANGYU ZHOU, SHANGWEI JI, YAN XU, JIANGBIN WANG Corresponding Author: SHAOYOU QIN Affiliations: China-Japan Union hospital of JiLin University; China-Japan Union hospital of JiLin University Objective: To explore the risk factors influencing the development of hepatitis C virus related primary liver cancer(HCV

related PLC),so as to promote the PLC screening in HCV and improve prognosis. Methods: A total of 122 patients(70 male,52 female,age 39∼83 years old,the average of age 59.9 ± 12.0 years old)were incorporated in this program. The study group contains 56 patients who were diagnosed as HCV related PLC(the group of PLC) ,and 66 patients with HCV infection were random choosed as control (the group of non-PLC). All patients were confirmed diagnosis in china-japan union hospital from 2007 to 2011.In the group of PLC,there were 44 male and 12 female patients whose average of age was 65.0 ± 8.2 years old.In the group of non-PLC,there were 26 male and 40 female patients whose average of age were 55.5 ± 13.1 years old. The diagnosis of HCV infection was based on serum HCV RNA and HCV Antibody detection using quantitative real-time FQ-PCR and the third generation Enzyme immunoassay (EIA) method separately.